Cycloastragenol (CAG) and Nicotinamide Mononucleotide (NMN) are two of the most researched compounds in longevity science. While both target cellular aging, they operate through fundamentally different mechanisms.
| Feature | Cycloastragenol (CAG) | NMN |
|---|---|---|
| Primary Target | Telomerase enzyme (hTERT upregulation) | NAD+ synthesis (NAMPT pathway) |
| Cellular Action | Maintains telomere length | Restores NAD+ levels for energy metabolism |
| Human RCT Data | Yes (Harley 2011, Salvador 2016, de Jaeger 2024) | Limited (mostly preclinical/animal) |
| Bioavailability Challenge | High hepatic first-pass (91.8% removal) | Degraded by CD38 in bloodstream |
| Delivery Solution | Liposomal encapsulation + cyclodextrin | Liposomal or sublingual forms |
| Typical Dose | 5-50mg daily | 250-1000mg daily |
Cycloastragenol is a triterpenoid saponin from Astragalus membranaceus. Research by Harley et al. (2011, PMID: 20822369) demonstrated that CAG activates telomerase in human cells. The Salvador 2016 RCT (n=117) showed telomere lengthening in CMV-positive adults over 12 months.
However, standard CAG faces severe bioavailability challenges. Zhu et al. (2010) documented 91.8% hepatic first-pass removal. TELOGENIS addresses this with a three-layer liposomal delivery matrix.
NMN is a direct precursor to Nicotinamide Adenine Dinucleotide (NAD+), a coenzyme essential for mitochondrial function, DNA repair, and sirtuin activation. NAD+ declines by approximately 50% between ages 40-60.
Many longevity researchers suggest that CAG and NMN may be complementary rather than competitive: